AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$SERA

Lindgardt Zhenya sold $14K of SERA

Lindgardt Zhenya (Chief Executive Officer) sold 7,022 shares of SERA PROGNOSTICS, INC. (SERA) at $2.00 on 2026-09-10.

Original reporting
SEC EDGAR · Lindgardt Zhenya
Published Sep 11, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock, but it provides transparency on insider holdings.

02

Market read

A routine insider sale with limited market impact; primarily of interest to compliance‑focused traders.

03

What to watch

Potential upcoming regulatory or product developments not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-11

Background

SEC Form 4 filings disclose insider transactions. This filing reports a sale by SERA's CEO.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

CEO Lindgardt Zhenya sold 7,022 shares of SERA at $2.00 each, total $14,044.

Expected impact

No material move expected; price may stay flat.

Evidence & confidence

The transaction size is modest relative to total holdings and market cap, and no broader catalyst is indicated.

Market effects

Sector

None; the sale does not affect the broader health‑care analytics sector.

Regional

None; the filing is specific to SERA and does not influence regional markets.

Global

None; the transaction is too small to affect global sentiment.

Counterpoint

What could challenge this read

If the CEO is reducing exposure, it could signal concerns about future performance.

Key entities

  • Person
    Lindgardt Zhenya

    Chief Executive Officer of SERA Prognostics, Inc.

  • Company
    SERA Prognostics, Inc.

    US‑listed provider of predictive analytics for the healthcare industry.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SERA insider trading history →

Related articles

AUG 19
$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

fool.com2 min
AUG 12
$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

prnewswire.com6 min
AUG 12
$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t

SEC EDGAR 8-K4 min